These 3 Catalysts Could Unlock Inovio's True Value

19-11-2013 DailyFinanceComments (0)

Biotechnologyimmatics biotechnologiesInovio PharmaceuticalsRoche

In addition, Roche is spreading its bets out -- it also signed a $1 billion deal with German company Immatics recently to access its portfolio of development-stage gastric, lung, and prostate cancer treatments. Nonetheless, any good news from either ...

Read more on DailyFinance

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top